Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBP-201 in Moderate to Severe Persistent Asthma with Type 2 Inflammation
2021-000583-30Phase 2Completed
- Sponsor
- Connect Biopharma
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing CBP-201 with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Started Oct 2021; status: completed.
02
Drugs
rademikibart
03
Conditions
asthma
Beyond the preview
Go deeper on 2021-000583-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000583-30.